Stocktoria

BridgeBio Oncology Therapeutics, Inc. BBOT

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-02-09

BridgeBio Oncology Therapeutics, Inc. statistics & valuation

Market cap$592.8M
P / B1.4×
Return on equity-32.6%
Return on capital-35.3%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
202320242025
Return on equity (%)
-32.60% 202320242025
Shares outstanding
28415 80.0M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-12.50% -45.20% -29.90% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
202320242025
EPS ($)
-$5756.41 -$4.30 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Return on assets-29.9%-45.2%-12.5%
Return on equity-32.6%41.6%0.0%
Current ratio12.348.10—

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.